TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06420518

Intervention type: OTHER
Intervention: Ketogenic diets
Description: During the outpatient phase of the study, all participants will undergo a very low-carbohydrate diet (less than 50grams/day) and, a fasting diet (12 hours) in a randomized order. Both diets are 6 days in duration and, will be interspaced by an inpatient insulin-suspension period. These ketogenic diets are implemented to drive higher ketone levels, within a safe threshold, to assess the accuracy of the CKM sensor. All the while, study participants will be wearing the CKM and, taking multiple daily ketone measurements with a standard point-of-cate ketone meter.

Intervention type: OTHER
Intervention: Ketogenic diets
Description: During the outpatient phase of the study, all participants will undergo a very low-carbohydrate diet (less than 50grams/day) and, a fasting diet (12 hours) in a randomized order. Both diets are 6 days in duration and, will be interspaced by an inpatient insulin-suspension period. These ketogenic diets are implemented to drive higher ketone levels, within a safe threshold, to assess the accuracy of the CKM sensor. All the while, study participants will be wearing the CKM and, taking multiple daily ketone measurements with a standard point-of-cate ketone meter.

Intervention type: OTHER
Intervention: 8-hour insulin-suspension period
Description: Interspaced between both ketogenic diets, on day 8 of the study, participants will have their insulin pumps suspended for 8 hours; therefore, participants will not receive any basal or bolus insulin. Ketone levels will be monitored on-site every 30 minutes with standard point-of-care capillary ketone meters and, if ketones measurements exceed the safety threshold, participants will be treated accordingly. Clearly defined stopping criteria and corrective treatments have been outlined in the study protocol to ensure participants safety.

Intervention type: OTHER
Intervention: 8-hour insulin-suspension period
Description: Interspaced between both ketogenic diets, on day 8 of the study, participants will have their insulin pumps suspended for 8 hours; therefore, participants will not receive any basal or bolus insulin. Ketone levels will be monitored on-site every 30 minutes with standard point-of-care capillary ketone meters and, if ketones measurements exceed the safety threshold, participants will be treated accordingly. Clearly defined stopping criteria and corrective treatments have been outlined in the study protocol to ensure participants safety.
Study: NCT06567691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS Gastrojejunostomy
Description: Endoscopic Ultrasound (EUS) Gastrojejunostomy. Under live real-time EUS visualization, a solution of normal saline or water and dilute methylene blue will be infused through the nasobiliary drainage catheter to mechanically distend the small intestine and create a suitable, expanded fluid-filled target for transgastric access. Once a suitable target has been identified, a lumen apposing metal stent (LAMS) will then be deployed securely across the newly created gastroenterostomy tract. Appropriate stent placement will be confirmed.
Study: NCT04180969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yohimbine + hydrocortisone
Description: yohimbine 54mg + hydrocortisone 20mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yohimbine + hydrocortisone
Description: yohimbine 54mg + hydrocortisone 20mg oral

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medial prefrontal cortex rTMS
Description: 1 Hz mPFC rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medial prefrontal cortex rTMS
Description: 1 Hz mPFC rTMS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: placebo stressor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo stressor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham rTMS
Description: sham mPFC rTMS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Description: sham mPFC rTMS
Study: NCT04946708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program (virtual/remote)
Description: Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program (virtual/remote)
Description: Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.
Study: NCT06567691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Gastrojejunostomy
Description: Gastrojejunostomy will be performed via an open technique using an upper midline or left sub-costal incision (at the discretion of the surgeon). An antecolic, pro-peristaltic, gastrojejunostomy will be performed using one of two standard techniques: 1) hand-sewn: 2-layer anastomosis using absorbable suture or 2) stapled: single-layer anastomosis using a surgical stapler with closed staple height ranging from 1.0 - 1.5 mm and suture closure of the common enterotomy. Feeding tube placement will be at the discretion of the operating surgeon and if performed, will be performed via a Stamm technique. Abdominal fascial closure will be performed with absorbable, monofilament, suture and skin will be closed using staples or suture at the discretion of the surgeon.
Study: NCT04702685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bandage will be placed in the presumed injection site while patients in under general anesthesia
Study: NCT05277402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG116
Description: IV infusion
Study: NCT05431465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita Ambria
Description: onlay restoration will be fabricated from Zirconia reinforced lithium disilicate glass ceramic(vita ambria)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPs emax onaly
Description: onlay restoration will be fabricated from lithium disilicate glass ceramic(IPS emax)
Study: NCT05864040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bitrack System-assisted laparoscopic radical/simple nephrectomy
Description: Robot-Assisted Laparoscopic Transperitoneal Radical/Simple Nephrectomy is performed under general anesthesia. Using blunt dissection, the inferior pole of the kidney is lifted, and ureter and gonadal veins released from fat and connective tissue. The ureter is dissected caudally and sectioned after being sealed with a distal endoscopic clip. Dissection proceeds along the psoas muscle with anterior elevation of the ureter and lower renal pole towards the hilium. Main hilar are circumferentially dissected and sectioned and the kidney is entirely mobilized and released. Gerota´s capsule and suprarenal gland may be preserved if oncologically safe. Once the specimen is completely released, a laparoscopic bag is introduced by the assistant and the specimen entrapped. The robot is undocked, gas evacuated from the abdomen and specimen retrieved. Abdominal wall incisions over 10mm are closed using a continuous suture. Skin incisions are closed using skin staplers.
Study: NCT05358834

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Oral melatonin administered as a single pill.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Oral melatonin administered as a single pill.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Oral melatonin administered as a single pill.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo administered as a single pill.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo administered as a single pill.
Study: NCT05823493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Schroth exercise therapy
Description: The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schroth exercise therapy
Description: The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
Study: NCT06340412

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch.
Description: 1) Sandwich with butter-like dairy product (40g milk fat) with intact MFGM.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM. One sandwich for breakfast and one sandwich for lunch.
Description: 2) Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sandwich with butter-like dairy product (40g milk fat) without MFGM. One sandwich for breakfast and one sandwich for lunch.
Description: 3) Sandwich with butter-like dairy product (40g milk fat) without MFGM.
Study: NCT06567691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Outlet Obstruction Scoring System (GOOSS)
Description: A previously validated instrument for assessing tolerance of oral intake.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Outlet Obstruction Scoring System (GOOSS)
Description: A previously validated instrument for assessing tolerance of oral intake.
Study: NCT06106295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metyrapone
Description: 250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)
Study: NCT05366660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interrogation/programming
Description: As the study investigates remote programming, we will describe two locations: local (patient side) and remote (expert side). Local support is defined by a physician or a technician under the direct responsibility of a nearby physician who connect the patient to the remote programming system. Similar to a conventional check-up, an external defibrillator will be located in the near vicinity of the patient. The patient will first be connected to the programmer as during a conventional follow-up. The programmer will then be connected to a local PC which captures the programmer VGA video output and controls the programmer through a mouse emulator. This local PC will be remotely controlled by the remote PC using Cisco Webex, a communication software used worldwide to support telemedicine.
Study: NCT06067230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection
Study: NCT04918628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: A humanized anti-PD-1 monoclonal antibody
Study: NCT04732897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic dressing
Description: Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band
Study: NCT05384145

Intervention type: OTHER
Group type: OTHER
Intervention: COAST-AL
Description: This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
Study: NCT06476093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib#12mg#PO#Q3W#d1-14# SRT#depends
Study: NCT06089330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: 240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib (Stivarga)
Description: 160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
Study: NCT06559631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indigenously Adapted CRA
Description: Treatment group will receive psychotherapy based on CRA which is an evidence based approach. This adapted version of CRA also consists emotional management, behavioral interventions, drug addiction treatment and islamically integrated psychotherapy for drug addiction and comorbid mental disorders.
Study: NCT05794685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle (adductor canal block).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle (adductor canal block).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4 in one block
Description: patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery (4 in one block).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4 in one block
Description: patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery (4 in one block).
Study: NCT05153304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: personalized vaccine
Description: Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
Study: NCT05375266

Intervention type: OTHER
Intervention: Sampling
Description: This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.

Intervention type: OTHER
Intervention: Sampling
Description: This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.
Study: NCT05153304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
Study: NCT05247567

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serum punction
Description: A blood sample inclusion and at the end of study visit
Study: NCT05676593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Libre 2
Description: The FSL will be placed on patient for 28 days to measure interstitial glucose
Study: NCT05224908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOS
Description: pelvimetry by EOS in standing and sitting position
Study: NCT05676593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic education
Description: Therapeutic education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Therapeutic education
Study: NCT05247567

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serum punction
Description: A blood sample inclusion and at the end of study visit

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: skin swab in elbow folds
Description: passage of a cotton swab in the crease of the elbow at the inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: skin swab in elbow folds
Description: passage of a cotton swab in the crease of the elbow at the inclusion
Study: NCT06298604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided standard fine needle biopsy
Description: Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 19-gauge standard fine needle biopsy device (Boston Scientific, USA) is inserted on it to obtain the sample or specimen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided motorized fine needle biopsy
Description: Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 20-gauge motorized fine needle biopsy device (Limaca, Israel) is inserted on it to obtain the sample or specimen.
Study: NCT05648253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyivy Intravaginal Device
Description: Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
Study: NCT06521879

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v probiotic support
Description: Addition of Lactobacillus plantarum 299v (L. plantarum 299v) probiotic supplementation to iron replacement therapy.
Study: NCT05476484

Intervention type: DRUG
Intervention: SQ SLIT-tablet
Description: SQ grass SLIT-tablet and/or SQ house dust mite SLIT-tablet
Study: NCT05507229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hillchol vaccine
Description: HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hillchol vaccine
Description: HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hillchol vaccine
Description: HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol Vaccine
Description: Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
Study: NCT06031051

Intervention type: DEVICE
Group type: OTHER
Intervention: Pillcam Crohn's Capsule Endoscopy
Description: Patients with scheduled colonoscopy are invited to a previous exploration with capsule endoscopy
Study: NCT04998149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peanut Ball positioning device
Description: Peanut Ball manufactured by Clinton industries at graylinemedical.com https://www.graylinemedical.com/products/clinton-industries-peanut-ball-peanut-ball-40-cm-yellow-8540?_pos=3\&_sid=d6e52e63c\&_ss=r